Literature DB >> 7593554

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

R Milo1, H Panitch.   

Abstract

Copolymer-1 (Cop-1) inhibits the T cell response to myelin basic protein (MBP), suppresses experimental autoimmune encephalomyelitis in many animal species, and was recently shown to be effective in the treatment of multiple sclerosis (MS). Interferon beta-1b (IFN-beta), an immune modulator with no antigenic specificity, is already approved for treatment of relapsing-remitting MS. We investigated the combined effect of these two agents on the cellular immune response to MBP. Antigen-specific Th1-like cell lines were generated from two healthy individuals with different MHC phenotypes. Cop-1 inhibited the proliferation of all MBP-specific lines but had no suppressive effect on tuberculin (PPD) or tetanus toxoid (TT)-specific T cell lines from either donor, while IFN-beta non-specifically reduced proliferation of all T cell lines. When combined in vitro, Cop-1 and IFN-beta had additive suppressive effects on proliferation of MBP-specific T cell lines, with 70-100% inhibition depending on the concentration of antigen. Synthesis of the pro-inflammatory cytokines interleukin-2 and IFN-gamma by MBP-specific lines was also inhibited additively (up to 100%). When antigen-presenting cells (APC) were pretreated with Cop-1, IFN-beta or both, T cell proliferation was inhibited in the same additive pattern, even though the inhibitors were not present in culture, indicating that they acted primarily through modulation of APC function. Additive effects were not found with PPD- or TT-specific cell lines. Pretreatment of APC with IFN-beta resulted in dose-dependent reduction in HLA-DR and HLA-DQ expression, which paralleled inhibition of T cell proliferation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593554     DOI: 10.1016/0165-5728(95)00085-g

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  Combination therapy in multiple sclerosis.

Authors:  Mark J Tullman; Fred D Lublin
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

2.  Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Aaron Boster; Mary Pat Bartoszek; Colleen O'Connell; David Pitt; Michael Racke
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

3.  1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study.

Authors:  P Sarchielli; O Presciutti; R Tarducci; G Gobbi; A Alberti; G P Pelliccioli; A Orlacchio; V Gallai
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

Review 4.  A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data.

Authors:  K P Johnson
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

5.  The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics.

Authors:  Jw Lindsey; Tf Scott; Sg Lynch; Ss Cofield; F Nelson; R Conwit; T Gustafson; Gr Cutter; Js Wolinsky; Fd Lublin
Journal:  Mult Scler Relat Disord       Date:  2012-02-23       Impact factor: 4.339

Review 6.  Combination therapy for multiple sclerosis: the treatment strategy of the future?

Authors:  Bianca Weinstock-Guttman; Rohit Bakshi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Interferon beta and glatiramer acetate therapy.

Authors:  Corey A McGraw; Fred D Lublin
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

8.  IFN-β inhibits the increased expression of IL-9 during experimental autoimmune uveoretinitis.

Authors:  Yan Yang; Liping Du; Min Sun; Aize Kijlstra; Peizeng Yang
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

9.  Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophy.

Authors:  Ehsan Afzal; Saba Zakeri; Peyman Keyhanvar; Meisam Bagheri; Parvin Mahjoubi; Mahtab Asadian; Nogol Omoomi; Mohammad Dehqanian; Negar Ghalandarlaki; Tahmineh Darvishmohammadi; Fatemeh Farjadian; Mohammad Sadegh Golvajoee; Shadi Afzal; Maryam Ghaffari; Reza Ahangari Cohan; Amin Gravand; Mehdi Shafiee Ardestani
Journal:  Int J Nanomedicine       Date:  2013-08-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.